Abstract
Epithelial–mesenchymal transition (EMT) programs operate within carcinoma cells, where they generate phenotypes associated with malignant progression. In their various manifestations, EMT programs enable epithelial cells to enter into a series of intermediate states arrayed along the E–M phenotypic spectrum. At present, we lack a coherent understanding of how carcinoma cells control their entrance into and continued residence in these various states, and which of these states favour the process of metastasis. Here we characterize a layer of EMT-regulating machinery that governs E–M plasticity (EMP). This machinery consists of two chromatin-modifying complexes, PRC2 and KMT2D-COMPASS, which operate as critical regulators to maintain a stable epithelial state. Interestingly, loss of these two complexes unlocks two distinct EMT trajectories. Dysfunction of PRC2, but not KMT2D-COMPASS, yields a quasi-mesenchymal state that is associated with highly metastatic capabilities and poor survival of patients with breast cancer, suggesting that great caution should be applied when PRC2 inhibitors are evaluated clinically in certain patient cohorts. These observations identify epigenetic factors that regulate EMP, determine specific intermediate EMT states and, as a direct consequence, govern the metastatic ability of carcinoma cells.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
Bulk and scRNA-seq data and CUT&RUN data that support the findings of this study have been deposited in the Gene Expression Omnibus (GEO) under accession code GSE158115. Human genome annotation data were obtained from Ensembl (https://useast.ensembl.org/Homo_sapiens/Info/Index). Clinical and normalized RNA-seq gene expression data for primary BRCA profiles as part of TCGA were obtained using Firehose (http://firebrowse.org/?cohort=BRCA). Mutation profiles of PRC2 and KMT2D-COMPASS component genes were obtained from cBioportal (https://www.cbioportal.org). Gene expression data of circulating tumour cells from breast cancer patients were from the GSE111065 dataset. All other data supporting the findings of this study are available from the corresponding author on reasonable request. Source data are provided with this paper.
Code availability
All the code will be available on reasonable request, including but not limited to the following: scRNA-seq analysis, bulk RNA-seq analysis and CUT&RUN data analysis.
References
Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189–196 (2016).
Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396–1401 (2014).
Puram, S. V. et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell 171, 1611–1624 (2017).
McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: past, present and the future. Cell 168, 613–628 (2017).
Meacham, C. E. & Morrison, S. J. Tumour heterogeneity and cancer cell plasticity. Nature 501, 328–337 (2013).
Flavahan, W. A., Gaskell, E. & Bernstein, B. E. Epigenetic plasticity and the hallmarks of cancer. Science 357, eaal2380 (2017).
Nieto, M. A., Huang, R. Y.-J., Jackson, R. A. & Thiery, J. P. EMT: 2016. Cell 166, 21–45 (2016).
Yang, J. et al. Guidelines and definitions for research on epithelial–mesenchymal transition. Nat. Rev. Mol. Cell Biol. 21, 341–352 (2020).
Lambert, A. W., Pattabiraman, D. R. & Weinberg, R. A. Emerging biological principles of metastasis. Cell 168, 670–691 (2017).
Aiello, N. M. & Kang, Y. Context-dependent EMT programs in cancer metastasis. J. Exp. Med. 216, 1016–1026 (2019).
Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704–715 (2008).
Lambert, A. W. & Weinberg, R. A. Linking EMT programmes to normal and neoplastic epithelial stem cells. Nat. Rev. Cancer 21, 325–338 (2021).
Singh, A. & Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741–4751 (2010).
Vega, S. et al. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev. 18, 1131–1143 (2004).
Saxena, M., Stephens, M. A., Pathak, H. & Rangarajan, A. Transcription factors that mediate epithelial–mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2, e179 (2011).
Dongre, A. et al. Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Res. 77, 3982–3989 (2017).
Kudo-Saito, C., Shirako, H., Takeuchi, T. & Kawakami, Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 15, 195–206 (2009).
Chen, L. et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat. Commun. 5, 5241 (2014).
Pastushenko, I. et al. Identification of the tumour transition states occurring during EMT. Nature 556, 463–468 (2018).
Jolly, M. K. et al. Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. Pharm. Ther. 194, 161–184 (2019).
Yuan, S., Norgard, R. J. & Stanger, B. Z. Cellular plasticity in cancer. Cancer Discov. 9, 837–851 (2019).
Fischer, K. R. et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527, 472–476 (2015).
Zheng, X. et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527, 525–530 (2015).
Ye, X. et al. Upholding a role for EMT in breast cancer metastasis. Nature 547, E1–E3 (2017).
Aiello, N. M. et al. Upholding a role for EMT in pancreatic cancer metastasis. Nature 547, E7–E8 (2017).
Li, Y. et al. Genetic fate mapping of transient cell fate reveals N-cadherin activity and function in tumor metastasis. Dev. Cell 54, 593–607 (2020).
Bornes, L. et al. Fsp1-mediated lineage tracing fails to detect the majority of disseminating cells undergoing EMT. Cell Rep. 29, 2565–2569 (2019).
Oft, M. et al. TGF-β1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 10, 2462–2477 (1996).
Lamouille, S., Xu, J. & Derynck, R. Molecular mechanisms of epithelial–mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15, 178–196 (2014).
Latil, M. et al. Cell-type-specific chromatin states differentially prime squamous cell carcinoma tumor-initiating cells for epithelial to mesenchymal transition. Cell Stem Cell 20, 191–204 (2017).
Yuan, S. et al. Global regulation of the histone mark H3K36me2 underlies epithelial plasticity and metastatic progression. Cancer Discov. 10, 854–871 (2020).
Elenbaas, B. et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 15, 50–65 (2001).
Chaffer, C. L. et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl Acad. Sci. USA 108, 7950–7955 (2011).
Wang, T. et al. Identification and characterization of essential genes in the human genome. Science 350, 1096–1101 (2015).
Yedier-Bayram, O. et al. EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities. Preprint at bioRxiv https://doi.org/10.1101/2021.05.14.444239 (2021).
Meeks, J. J. & Shilatifard, A. Multiple roles for the MLL/COMPASS family in the epigenetic regulation of gene expression and in cancer. Annu. Rev. Cancer Biol. 1, 425–446 (2017).
Margueron, R. & Reinberg, D. The Polycomb complex PRC2 and its mark in life. Nature 469, 343–349 (2011).
Piunti, A. & Shilatifard, A. Epigenetic balance of gene expression by Polycomb and COMPASS families. Science 352, aad9780 (2016).
Dhar, S. S. et al. MLL4 is required to maintain broad H3K4me3 peaks and super-enhancers at tumor suppressor genes. Mol. Cell 70, 825–841 (2018).
Skene, P. J. & Henikoff, S. An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites. eLife 6, e21856 (2017).
Michalak, E. M. et al. Canonical PRC2 function is essential for mammary gland development and affects chromatin compaction in mammary organoids. PLoS Biol. 16, e2004986 (2018).
Trapnell, C. et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat. Biotechnol. 32, 381–386 (2014).
Malanchi, I. et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481, 85–89 (2011).
Fazilaty, H. A gene regulatory network to control EMT programs in development and disease. Nat. Commun. 10, 5115 (2019).
Ye, X. et al. Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature 525, 256–260 (2015).
Moody, S. E. et al. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8, 197–209 (2005).
Göllner, S. et al. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. Nat. Med. 23, 69–78 (2017).
Pastushenko, I. et al. Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis. Nature 589, 448–455 (2020).
Comet, I., Riising, E. M., Leblanc, B. & Helin, K. Maintaining cell identity: PRC2-mediated regulation of transcription and cancer. Nat. Rev. Cancer 16, 803–810 (2016).
Kleer, C. G. et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100, 11606–11611 (2003).
Wassef, M. et al. Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis. Genes Dev. 29, 2547–2562 (2015).
Holm, K. et al. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol. Oncol. 6, 494–506 (2012).
Serresi, M. et al. Polycomb Repressive Complex 2 is a barrier to KRAS-driven inflammation and epithelial-mesenchymal transition in non-small-cell lung cancer. Cancer Cell 29, 17–31 (2016).
Cardenas, H., Zhao, J., Vieth, E., Nephew, K. P. & Matei, D. EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells. Oncotarget 7, 84453–84467 (2016).
Hu, Y. & Smyth, G. K. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods 347, 70–78 (2009).
Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
Mi, H., Muruganujan, A., Casagrande, J. T. & Thomas, P. D. Large-scale gene function analysis with the PANTHER classification system. Nat. Protoc. 8, 1551–1566 (2013).
Griffiths, J. A., Richard, A. C., Bach, K., Lun, A. T. L. & Marioni, J. C. Detection and removal of barcode swapping in single-cell RNA-seq data. Nat. Commun. 9, 2667 (2018).
Lun, A. T. L. et al. EmptyDrops: distinguishing cells from empty droplets in droplet-based single-cell RNA sequencing data. Genome Biol. 20, 63 (2019).
Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888–1902 (2019).
Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012).
Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).
Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841–842 (2010).
Shen, L., Shao, N., Liu, X. & Nestler, E. ngs.plot: quick mining and visualization of next-generation sequencing data by integrating genomic databases. BMC Genomics 15, 284 (2014).
Ramírez, F. et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 44, W160-5 (2016).
Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24–26 (2011).
Acknowledgements
We thank S. Henikoff for providing pA-MNase and yeast DNA for the CUT&RUN experiment. We are grateful to R. Goldsby, O. Rozenblatt-Rosen, G. Bell and all members of the R.A.W. laboratory for discussion and suggestions. We thank the Flow Cytometry Core Facility, the Genome Technology Core, Bioinformatics and Research Computing Core at Whitehead Institute, and MIT Koch Institute Histology Facility for technical assistance. This research was supported by MIT Stem Cell Initiative, the Breast Cancer Research Foundation, the Advanced Medical Research Foundation and the Ludwig Center for Molecular Oncology, National Cancer Institute Program R01-CA078461 (R.A.W.), R35-CA220487 (R.A.W.) and Susan G. Komen Postdoctoral Fellowship no. PDF15301255 (Y.Z.). A.W.L. was supported by an American Cancer Society—New England Division—Ellison Foundation Postdoctoral Fellowship (PF-15-131-01-CSM) and a postdoctoral fellowship from the Ludwig Center for Molecular Oncology at MIT. M.M.W. was supported by the David H. Koch Graduate Fellowship. T.B.-O. is funded by the Scientific and Technological Research Council of Turkey (TUBITAK#216S461). T.B.-O., T.T.O. and N.A.L. are funded by the Koç University Research Center for Translational Medicine (KUTTAM), funded by the Presidency of Strategy and Budget of Turkey. J.A.L. is the D.K. Ludwig Professor for cancer research. R.A.W. is an American Cancer Society research professor and a Daniel K. Ludwig Foundation cancer research professor.
Author information
Authors and Affiliations
Contributions
Y.Z. conceived the project, designed and performed the experiments, analysed data and prepared the manuscript with input from all the authors. J.L.D. provided technical support to Y.Z. S.D. and Y.Z. performed CUT&RUN experiments. X.L., F.R., S.D. and Y.Z. performed mouse surgeries and tumour growth monitoring. A.W.L. provided technical support in tumoursphere assays and edited the manuscript. J.A.K., Y.Z., M.H. and A.R. designed, performed and analysed the scRNA-seq experiments. P.T., M.T. and I.T. provided technical support in bioinformatic analysis. H.R.K., M.K., O.Y.-B., N.A.L., T.T.O. and T.B.-O. provided experimental design input and technical support for CRISPR screening experiments. M.M.W. and J.A.L. provided technical support in histology studies. R.A.W. designed and supervised this study and edited the manuscript.
Corresponding authors
Ethics declarations
Competing interests
A.R. is a co-founder and equity holder of Celsius Therapeutics, an equity holder of Immunitas and was a SAB member of Neogene Therapeutics, Thermo Fisher Scientific, Asimov and Syros Pharmaceuticals until 31 July 2020. Since 1 August 2020, A.R. has been an employee of Genentech, a member of the Roche group. R.A.W. has a consulting agreement with Verastem Inc., together with holding shares of this company. The other authors declare no competing interests.
Peer review
Peer review information
Nature Cell Biology thanks Binhua Zhou, Xiang Zhang and the other, anonymous, reviewers for their contribution to the peer review of this work. Peer reviewer reports are available.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data
Extended Data Fig. 1 HMLER epithelial cells show differential EMP which is associated with different TGF-β responses.
a,b, Flow cytometry of the CD44 and CD104 cell-surface staining of HMLER cells (a) and Bright-phase microscopy (b) of FACS-sorted CD44hi mesenchymal cells and CD44lo epithelial cells. Scale bar, 20 𝜇m. n = 3 biologically independent experiments. c, Immunofluorescence staining shows adherent junction protein E-cadherin in FACS-sorted CD44hi mesenchymal cells and CD44lo epithelial cells. Scale bar, 20 𝜇m. n = 2 biologically independent experiments. d, Flow cytometry of the CD44 and CD104 cell-surface staining using CD44lo epithelial population sorted from C1 and C2 cells. Data were collected at 1 and 5 days after sorting. e, UMAP plots showing expression levels of epithelial marker genes EPCAM, DSP and mesenchymal marker genes CDH2, ZEB1, ZEB2 and PRRX1 in HMLER/C1/C2 cells. f, mRNA expression levels of TGFB1, TGFBR2, TGFBR1, SMAD2, SMAD3 and SMAD4 in C1, and C2-Epi cells. n=3. n.s., not significant. g. ELISA assay shows TGF-β1 protein secreted by C1 and C2-Epi cells. n=3. **, p = 0.009. h, Immunoblot of phosphor-Smad2 and total Smad2 in C1 and C2-Epi cells, as well as C1 cells treated with DMSO or SB-431542 (5 𝜇M). GAPDH as loading control. n = 2 biologically independent experiments. i, Normalized cell number of C1 and C2-Epi cells after five-day culture in control, TGF-β (2 ng/ml) and SB-431542 (5 𝜇M) treated conditions. n=6. *, p = 0.03; ***, p < 0.001. j, Percentage of CD44hi mesenchymal population of C1 and C2-Epi cells after five-day culture in control, TGF-β (2 ng/ml) and SB-431542 (5 𝜇M) treated conditions. n=3. ***, p < 0.001. Statistical analysis was performed using unpaired two-tailed Student t-tests (f,g) or one-way ANOVA followed by Tukey multiple-comparison analysis (i,j). Data are presented as mean ± SEM. Numerical source data are provided.
Extended Data Fig. 2 CRISPR screening identifies EMP regulators.
a, Gating strategies used in FACS analysis and the CRISPR screens. One C2-Epi initiated primary tumor was used as an example. b, Flow cytometry of the CD44 and EpCAM cell-surface staining of HMLER cells, demonstrating CD44hi mesenchymal cell population does not express EpCAM. c, EpCAM-based magnetic-activated cell sorting (MACS) enriches CD44lo epithelial cells in MACS-EpCAMpos population and CD44hi mesenchymal cells in MACS-EpCAMneg population. d, A summary of EPIKOL sgRNA library content. e, Diagram of the EPIKOL CRISPR screening using non-convertible C1 cells to identify possible regulators of E–M plasticity. f, List of significantly enriched GO cellular components terms from the EPIKOL CRISPR screening. Numerical source data are provided.
Extended Data Fig. 3 PRC2 and KMT2D-COMPASS regulate EMP.
a, Sanger sequencing demonstrate complete knock-out of ASH2L, EED and KMT2D genes in the corresponding clonal cells. b, Percentage of CD44hi mesenchymal population in C1 cells transduced with sgRNAs targeting SETD1A, SETD1B, KMT2A, KMT2B, KMT2C and KMT2D respectively. n=3. ***, p<0.001. Statistical analysis was performed using one-way ANOVA followed by Dunnett multiple-comparison analysis. Data are presented as mean ± SEM. c, Flow cytometry analysis shows the CD44 and CD104 cell-surface staining of sorted epithelial subpopulation from C1-sgEED and C1-sgKMT2D cells (left) and the quantification of CD44hi mesenchymal population in different culture conditions (right). Cells were cultured in control (DMSO) or SB-431542 (5 𝜇M) treated condition in vitro for 5 days. n=3. **, p = 0.001 (C1-sgEED-Epi), 0.007 (C1-sgKMT2D-Epi). Statistical analysis was performed using unpaired two-tailed Student t-tests. Data are presented as mean ± SEM. d, Flow cytometry of the CD44 cell-surface staining of C3-sgControl, C3-sgEED and C3-sgKMT2D cells at the population level. e, Flow cytometry of the EpCAM cell-surface staining of HCC827-sgControl, HCC827-sgEED and HCC827-sgKMT2D cells at the population level. f. Flow cytometry of cell-surface EpCAM in SUM149D2-sgControl, SUM149D2-sgEED and SUM149D2-sgKMT2D cells at the population level. g, Immortalized but not transformed HMLE epithelial cells contain convertible (nrc-4) and non-convertible (nrc-1) single cell clones. RAS transformation promotes EMT in convertible clone but not in non-convertible clone. h, Immunoblot of E-cadherin, N-cadherin, and ZEB1 in representative HMLE clones before and after RAS oncogene transformation. GAPDH as loading control. n = 2 biologically independent experiments. i, Flow cytometry of the CD44 and CD104 cell-surface staining of HMLE-nrc-1-sgControl, HMLE-nrc-1-sgEED and HMLE-nrc-1-sgKMT2D cells in control or TGF-β treated (2 ng/ml) conditions for 7 days. HMLE-nrc-1 is a clonal cell population generated from HMLE that stably reside in an epithelial state. Numerical source data are provided.
Extended Data Fig. 4 PRC2 directly binds to the promoters of several EMT-TF genes and KMT2D-KO changes H3K27me3 genomic distribution.
a, Heatmap showing the global binding pattern of PRC2 (as measured by EZH2 CUT&RUN profiles) at promoter regions in C1-sgControl, C1-sgEED-Epi and C1-sgKMT2D-Epi cells. b, Immunoblot of H3K27me3 and H3K3me1/2/3 in C1-sgControl, C1-sgEED-Epi and C1-KMT2D-Epi cells. Total H3 as loading control. n = 2 biologically independent experiments. c, Majority of PRC2 direct target genes were upregulated after EED knockout. d, Ectopic expression of EMT-TF ZEB1 is sufficient to activate an EMT program in C1 cells. e, Heatmap displaying the global COMPASS (as measured by ASH2L CUT&RUN profiles) occupancy in C1-sgControl, C1-sgEED-Epi, and C1-sgKMT2D-Epi cells. f, Heatmap showing mRNA expression levels of the 413 PRC2 direct genes. g, Heatmap showing all H3K27me3 peaks in C1-sgControl, C1-sgEED-Epi and C1-sgKMT2D-Epi cells. h, Average H3K27me3 signal of all H3K27me3 peaks in C1-sgControl, C1-sgEED-Epi and C1-sgKMT2D-Epi cells. i, Heatmap showing the top 2000 H3K27me3 peaks in C1-sgControl cells and the H3K27me3 signals in these same regions in C1-sgEED-Epi and C1-sgKMT2D-Epi cells. j, Average H3K27me3 signal of the top 2000 H3K27me3 peaks in C1-sgControl cells and average H3K27me3 signal in these regions in C1-sgEED-Epi and C1-sgKMT2D-Epi cells.
Extended Data Fig. 5 EED-KO and KMT2D-KO generate distinct mesenchymal cell states.
a, UMAP plots showing expression levels of epithelial marker genes CDH1, EPCAM, DSP and mesenchymal marker genes ZEB1, ZEB2 and TWIST1 in C1-sgControl, C1-sgEED and C1-sgKMT2D cells. b, Immunoblot of EMT-TFs SNAIL, ZEB1, EMT markers E-cadherin, pan-cytokeratines and EED, KMT2D in SUM149D2-sgControl, SUM149D2-sgEED-Mes and SUM149D2-sgKMT2D-Mes cells. n = 2 biologically independent experiments.
Extended Data Fig. 6 EED-KO quasi-mesenchymal cells show elevated ability in forming metastases.
a, Growth curve of C1-sgControl, C1-sgEED-Mes and C1-sgKMT2D-Mes cells in vitro. n=3. *, p = 0.03; **, p = 0.005. n.s., not significant. b, Quantification of mammosphere formation by C1-sgControl, C1-sgEED-Mes and C1-sgKMT2D-Mes cells. n=3. ***, p<0.001. c, Differences in primary tumor-initiating ability of C1-sgControl, C1-sgEED-Mes and C1-sgKMT2D-Mes cells upon transplantation with limiting dilution into NSG mice. Tumors that arose from transplantation of 2 × 106 cells were of similar size. n=5 in each group. d,e, Representative bright-phase and fluorescence microscopy (d) and number of metastatic nodules (e) shows metastatic outgrowths in the lung of C1-sgControl, C1-sgEED-Mes and C1-sgKMT2D-Mes cells 8 weeks after fat pad implantation. n=5 in each group. ***, p<0.001. n.s., not significant. Statistical analysis was performed using one-way ANOVA followed by Tukey multiple-comparison analysis. Data are presented as mean ± SEM. Numerical source data are provided.
Extended Data Fig. 7 PRC2 loss of function mutations and the EED-KO gene signature associate with poor prognosis in breast cancer patients.
a, OncoPrint (cBioPortal) showing patients with loss of function mutations of PRC2 component genes in Metastatic Breast Cancer Project patient cohort. b, OncoPrint (cBioPortal) showing patients with amplification of PRC2 component genes in TCGA breast patient cohort. c, Kaplan-Meier survival (log-rank Mantel-Cox test) of TCGA breast cancer patients with or without amplification of PRC2 component genes. d, A proportion of breast cancer patient-derived CTCs was associated with the EED-KO gene signature. scRNA-seq data were derived from GSE111065 dataset. Grey circles highlight CTCs associated with the EED-KO signature.
Extended Data Fig. 8 PRC2 inhibitor treatment induces a metastatic, quasi-mesenchymal cell state.
a, Time-course flow cytometry analysis of the EpCAM cell-surface staining of C1 cells treated with different combinations of TGF-β (2ng/ml), SB-431542 (5𝜇M), EED226 (10𝜇M) and Tazemetostat (TAZ) (10𝜇M). b, Immunoblot of E-cadherin, N-cadherin, Periostin in MCF10A cells treated with different combinations of TGF-β (2ng/ml), EED226 (10𝜇M) and Tazemetostat (TAZ) (10𝜇M) for 10 days. GAPDH as loading control. c,d, Flow cytometry analysis of the CD44 (c) and EpCAM (d) cell-surface staining of C1 parental cells or C1-226-Mes, C1-sgEED-Mes and C1-sgKMT2D-Mes cells upon withdrawal of PRC2 inhibitors and addition of SB-431542 (5𝜇M).
Supplementary information
Source data
Source Data Fig. 1
Unprocessed western blots.
Source Data Fig. 2
Statistical source data.
Source Data Fig. 3
Statistical source data.
Source Data Fig. 3
Unprocessed western blots.
Source Data Fig. 4
Statistical source data.
Source Data Fig. 6
Statistical source data.
Source Data Fig. 6
Unprocessed western blots.
Source Data Extended Data Fig. 1
Statistical source data.
Source Data Extended Data Fig. 1
Unprocessed western blots.
Source Data Extended Data Fig. 2
Statistical source data.
Source Data Extended Data Fig. 3
Statistical source data.
Source Data Extended Data Fig. 3
Unprocessed western blots.
Source Data Extended Data Fig. 4
Unprocessed western blots.
Source Data Extended Data Fig. 5
Unprocessed western blots.
Source Data Extended Data Fig. 6
Statistical source data.
Source Data Extended Data Fig. 8
Unprocessed western blots.
Rights and permissions
About this article
Cite this article
Zhang, Y., Donaher, J.L., Das, S. et al. Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasis. Nat Cell Biol 24, 554–564 (2022). https://doi.org/10.1038/s41556-022-00877-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41556-022-00877-0
This article is cited by
-
Lung endothelium exploits susceptible tumor cell states to instruct metastatic latency
Nature Cancer (2024)
-
Combinatorial Cooperativity in miR200-Zeb Feedback Network can Control Epithelial–Mesenchymal Transition
Bulletin of Mathematical Biology (2024)
-
NUAK1 promotes tumor metastasis through upregulating slug transcription in esophageal squamous cell carcinoma
Cancer Cell International (2023)
-
The circadian clock circuitry deconvolutes colorectal cancer and lung adenocarcinoma heterogeneity in a dynamic time-related framework
Cancer Gene Therapy (2023)
-
Reactivation of embryonic genetic programs in tissue regeneration and disease
Nature Genetics (2023)